Cargando…

Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer

BACKGROUND: Liquid biopsy offers a minimally invasive alternative to tissue-based evaluation of mutational status in cancer. The goal of the present study was to evaluate the aggregate performance of OncoBEAM RAS mutation analysis in plasma of colorectal cancer (CRC) patients at 10 hospital laborato...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Foncillas, Jesús, Tabernero, Josep, Élez, Elena, Aranda, Enrique, Benavides, Manuel, Camps, Carlos, Jantus-Lewintre, Eloisa, López, Rafael, Muinelo-Romay, Laura, Montagut, Clara, Antón, Antonio, López, Guillermo, Díaz-Rubio, Eduardo, Rojo, Federico, Vivancos, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288144/
https://www.ncbi.nlm.nih.gov/pubmed/30467411
http://dx.doi.org/10.1038/s41416-018-0293-5
_version_ 1783379740822863872
author García-Foncillas, Jesús
Tabernero, Josep
Élez, Elena
Aranda, Enrique
Benavides, Manuel
Camps, Carlos
Jantus-Lewintre, Eloisa
López, Rafael
Muinelo-Romay, Laura
Montagut, Clara
Antón, Antonio
López, Guillermo
Díaz-Rubio, Eduardo
Rojo, Federico
Vivancos, Ana
author_facet García-Foncillas, Jesús
Tabernero, Josep
Élez, Elena
Aranda, Enrique
Benavides, Manuel
Camps, Carlos
Jantus-Lewintre, Eloisa
López, Rafael
Muinelo-Romay, Laura
Montagut, Clara
Antón, Antonio
López, Guillermo
Díaz-Rubio, Eduardo
Rojo, Federico
Vivancos, Ana
author_sort García-Foncillas, Jesús
collection PubMed
description BACKGROUND: Liquid biopsy offers a minimally invasive alternative to tissue-based evaluation of mutational status in cancer. The goal of the present study was to evaluate the aggregate performance of OncoBEAM RAS mutation analysis in plasma of colorectal cancer (CRC) patients at 10 hospital laboratories in Spain where this technology is routinely implemented. METHODS: Circulating cell-free DNA from plasma was examined for RAS mutations using the OncoBEAM platform at each hospital laboratory. Results were then compared to those obtained from DNA extracted from tumour tissue from the same patient. RESULTS: The overall percentage agreement between plasma-based and tissue-based RAS mutation testing of the 236 participants was 89% (210/236; kappa, 0.770 (95% CI: 0.689–0.852)). Re-analysis of tissue from all discordant cases by BEAMing revealed two false negative and five false positive tumour tissue RAS results, with a final concordance of 92%. Plasma false negative results were found more frequently in patients with exclusive lung metastatic disease. CONCLUSIONS: In this first prospective real-world RAS mutation performance comparison study, a high overall agreement was observed between results obtained from plasma and tissue samples. Overall, these findings indicate that the plasma-based BEAMing assay is a viable solution for rapid delivery of RAS mutation status to determine mCRC patient eligibility for anti-EGFR therapy.
format Online
Article
Text
id pubmed-6288144
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-62881442019-06-21 Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer García-Foncillas, Jesús Tabernero, Josep Élez, Elena Aranda, Enrique Benavides, Manuel Camps, Carlos Jantus-Lewintre, Eloisa López, Rafael Muinelo-Romay, Laura Montagut, Clara Antón, Antonio López, Guillermo Díaz-Rubio, Eduardo Rojo, Federico Vivancos, Ana Br J Cancer Article BACKGROUND: Liquid biopsy offers a minimally invasive alternative to tissue-based evaluation of mutational status in cancer. The goal of the present study was to evaluate the aggregate performance of OncoBEAM RAS mutation analysis in plasma of colorectal cancer (CRC) patients at 10 hospital laboratories in Spain where this technology is routinely implemented. METHODS: Circulating cell-free DNA from plasma was examined for RAS mutations using the OncoBEAM platform at each hospital laboratory. Results were then compared to those obtained from DNA extracted from tumour tissue from the same patient. RESULTS: The overall percentage agreement between plasma-based and tissue-based RAS mutation testing of the 236 participants was 89% (210/236; kappa, 0.770 (95% CI: 0.689–0.852)). Re-analysis of tissue from all discordant cases by BEAMing revealed two false negative and five false positive tumour tissue RAS results, with a final concordance of 92%. Plasma false negative results were found more frequently in patients with exclusive lung metastatic disease. CONCLUSIONS: In this first prospective real-world RAS mutation performance comparison study, a high overall agreement was observed between results obtained from plasma and tissue samples. Overall, these findings indicate that the plasma-based BEAMing assay is a viable solution for rapid delivery of RAS mutation status to determine mCRC patient eligibility for anti-EGFR therapy. Nature Publishing Group UK 2018-11-23 2018-12-11 /pmc/articles/PMC6288144/ /pubmed/30467411 http://dx.doi.org/10.1038/s41416-018-0293-5 Text en © The Author(s) 2018 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
García-Foncillas, Jesús
Tabernero, Josep
Élez, Elena
Aranda, Enrique
Benavides, Manuel
Camps, Carlos
Jantus-Lewintre, Eloisa
López, Rafael
Muinelo-Romay, Laura
Montagut, Clara
Antón, Antonio
López, Guillermo
Díaz-Rubio, Eduardo
Rojo, Federico
Vivancos, Ana
Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
title Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
title_full Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
title_fullStr Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
title_full_unstemmed Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
title_short Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
title_sort prospective multicenter real-world ras mutation comparison between oncobeam-based liquid biopsy and tissue analysis in metastatic colorectal cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288144/
https://www.ncbi.nlm.nih.gov/pubmed/30467411
http://dx.doi.org/10.1038/s41416-018-0293-5
work_keys_str_mv AT garciafoncillasjesus prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer
AT tabernerojosep prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer
AT elezelena prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer
AT arandaenrique prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer
AT benavidesmanuel prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer
AT campscarlos prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer
AT jantuslewintreeloisa prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer
AT lopezrafael prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer
AT muineloromaylaura prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer
AT montagutclara prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer
AT antonantonio prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer
AT lopezguillermo prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer
AT diazrubioeduardo prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer
AT rojofederico prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer
AT vivancosana prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer